Alcon receives FDA approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
AcrySof IQ Aspheric Intraocular Lens (IOL) with UltraSert pre-loaded delivery system helps maintain integrity of incision while facilitating smooth IOL delivery.
Alcon has received FDA approval for its AcrySof IQ Aspheric IOL with the UltraSert pre-loaded delivery system for patients undergoing cataract surgery. This new delivery system combines the control of a manually loaded device with the safety and convenience of a disposable, pre-loaded injector to optimize the implantation of the AcrySof IQ Aspheric IOL into the cataract patient's eye. Nearly four million cataract surgeries are performed each year in the US. The UltraSert pre-loaded delivery system received the European CE mark in June 2015.
"The introduction of the UltraSert pre-loaded delivery system further reinforces our commitment to advancing cataract surgery through innovation," said Sergio Duplan, Region President, US and Canada. "We are addressing a distinct need of cataract surgeons for a single-use system that maximizes their control during surgery and helps them streamline procedures to enable improved patient outcomes."
In cataract surgery, controlling the speed of delivery of the IOL when inserted into the eye is an important factor in achieving a successful cataract procedure. Alcon has addressed this critical factor in the UltraSert pre-loaded delivery system with the TensionGlide plunger, a spring-controlled mechanism designed for a smooth, controlled delivery of the AcrySof IQ IOL into the capsular bag. In addition, the UltraSert pre-loaded delivery system features a plunger tip which is designed to support consistent IOL folding and precise placement into the capsular bag of the eye.
The design of the new UltraSert pre-loaded delivery system also helps to create a less invasive corneal incision during cataract surgery. The smaller nozzle tip allows for a corneal incision down to 2.2 mm for insertion of the IOL while the Depth Guard nozzle of the delivery system prevents the device from being inserted deeper into the incision than necessary, preserving the size of the original corneal incision.
"In testing this device, I was immediately impressed with its smooth control and single hand delivery," said Dr Robert Lehmann, a practicing ophthalmologist at the Lehmann Eye Center of Nacogdoches, Texas, USA. "I believe it will give the surgeon excellent control during the procedure to ensure a consistent delivery of the IOL into the eye. There are many surgeons who are highly interested in pre-loaded devices, and UltraSert represents a major step forward in pre-loaded delivery system technology."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance